Susan G. Komen Central and South Jersey will be hosting a networking and educational dinner allowing guests to meet and speak with dedicated breast cancer specialists at the Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, on February 10, 2020. This event focuses on networking with guests and the opportunity to hear from three scholars in the field of breast cancer research and treatment.
Enjoy an evening of networking, dinner and an education program hosted by Dr. M. Michele Blackwood, Chief, Section of Breast Surgery, Rutgers Cancer Institute of New Jersey and Medical Director, Northern Regional Director of Breast Services for RWJBarnabas Health and Dr. Deborah Toppmeyer, Chief Medical Officer and Director of the Stacy Goldstein Breast Cancer Center and the LIFE Center at Rutgers Cancer Institute of New Jersey, featuring Komen Scholar Dr. Ben Ho Park who will be presenting on Genetic Alterations as New Targets for Breast Cancer Therapy.
Dr. Ben Ho Park M.D., Ph.D., is the Donna Hall Professor of Medicine at Vanderbilt University Medical Center and is the featured speaker for the evening. He is also Co-Leader of the Breast Cancer Research Program, Associate Director for Translational Research and Director of Precision Oncology for Vanderbilt-Ingram Cancer Center.
Dr. Park’s research focuses on using genetic models to identify, validate and develop targeted therapies for breast cancer. He specifically studies the PI3 Kinase/AKT signaling pathway and his work identified a high frequency of mutation in the PIK3CA gene in human breast cancers, opening the door for PI3K-targeted therapies in breast cancer. With Komen-funding, Dr. Park is pursuing his efforts in precision oncology: specific drugs to specific patients, focusing on targeting mutations in a gene called SF3B1 that are present only in cancer cells and not normal cells. With Komen funding, Dr. Park is pursuing his efforts in precision oncology: specific drugs to specific patients, focusing on targeting mutations in a gene called SF3B1 that are present only in cancer cells and not normal cells.
Both Drs. Toppmeyer and Blackwood are national leaders and have been at the forefront of breast cancer research and care for more than 25 years. They have contributed to the advances of breast cancer treatment, prevention and diagnosis.
Dr. Blackwood has seen that “The patients who take in the disease, do the treatments, listen to their doctors and change their lifestyle habits: they do well.” Meet Dr. Park, Dr. Toppmeyer, and Dr. Blackwood and learn more about the advances made in breast cancer care and treatment at the 2020 Networking and Komen Scholar Dinner. Visit komencsnj.org/komenscholar to get your tickets and enjoy an evening featuring plentiful networking opportunities, dinner, and words from our special guests.